Mizuho Securities has lowered its price target on Tesla Inc. (NASDAQ: TSLA) to $325 from $375 after the EV giant reported disappointing Q1 results. Despite the downgrade, the brokerage maintained its "Outperform" rating, citing optimism around Tesla’s upcoming low-cost models and autonomous vehicle ambitions.
Tesla’s first-quarter earnings fell short on both top and bottom lines. The company posted earnings per share of $0.27, missing Wall Street’s estimate of $0.44. Revenue also came in below expectations at $19.3 billion versus the $21.4 billion consensus. Mizuho noted the underperformance was anticipated, yet still sees an 8% year-over-year decline in Tesla’s 2025 deliveries, following the firm’s withdrawal of its annual guidance.
However, Mizuho remains bullish on Tesla’s longer-term growth potential. Analysts highlighted the expected launch of a low-cost Model Y in the first half of 2025 and the rollout of Tesla’s autonomous Cybercab in early 2026 as key catalysts. Despite reports suggesting delays to 2026, Mizuho believes the Model Y launch is still on track, though production ramp-up may be slower than initially projected.
The brokerage emphasized Tesla’s continued leadership in the U.S. EV market, which could help cushion losses stemming from fierce competition and political backlash in China and parts of Europe.
Elon Musk, Tesla’s CEO, also pledged to shift focus back to the company by stepping back from his government-related duties starting in May—a move that sparked a rally in Tesla shares despite weak earnings.
With Tesla navigating challenges from global EV competition and political scrutiny, Mizuho sees its innovation pipeline as a critical driver of future growth.


Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 



